1/4/2016 2:00:00 AM
KineMed Inc. today announced that it has entered into a strategic collaboration with Pfizer Inc. (NYSE:PFE) to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.
9/24/2015 1:00:00 AM
KineMed, Inc. announced today that it has entered into an agreement with BioPharma Forest, Inc. to develop and commercialize synthetic Ghrelin.
6/2/2015 1:00:00 AM
KineMed, Inc. and Pronutria Biosciences, Inc. announced today a collaboration under which KineMed will apply its dynamic proteomics platform to assist Pronutria in evaluating novel biologics designed to restore cellular homeostasis in amino acid biology.
4/23/2015 1:00:00 AM
KineMed, Inc. and Camino Partnership, LLC today announced they are entering into a strategic partnership to locate and acquire control of a portfolio of new drug and targeted drug candidates. Once acquired, the collaboration will apply KineMed’s dynamic proteomics technology to carry out rapid proof‐of‐concept clinical studies for subsequent outlicensing to pharmaceutical companies. The initial therapeutic areas of focus will be oncology, neurodegenerative disorders, muscle wasting and fibrosis, particularly fibrosis of the liver. The collaboration intends to carry out de‐risking proof‐of‐concept studies on up to six compounds over a three‐year period.
2/9/2015 2:00:00 AM
EMERYVILLE, CA, February 9, 2015 – KineMed, Inc. announced today that David Fineman, KineMed’s Chairman and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference, on Monday, February 9th at 9:15 AM EST, in the Park South Room of the Waldorf Astoria New York.
11/18/2014 2:00:00 AM
KineMed, Inc. announced today that two Chronic Lymphocytic Leukemia (CLL) studies utilizing KineMed’s proprietary kinetic biomarker technology will be presented at the American Society of Hematology Annual Meeting taking place December 6-9, 2014 in San Francisco, California. KineMed’s CLL research collaborators, Jan A. Burger, MD, Ph.D., of the MD Anderson Cancer Center, and Elizabeth J. Murphy, MD, DPhil, from the University of California San Francisco Department of Medicine and representing the CLL Research Consortium investigators, will present the studies at the conference.
11/4/2014 2:00:00 AM
KineMed, Inc. announced today that it has been awarded a three-year grant by the Bill & Melinda Gates Foundation to apply its novel, proprietary non-invasive measurement of skeletal muscle mass to pre-term and full-term infants and young children. The Principal Investigator, William Evans, Ph.D., is head of the KineMed Division of Muscle and Health. The study will, for the first time, measure changes in skeletal muscle mass during one year of growth. The information from this project will provide new information to better assess the effects of nutritional status and other factors that result in the loss of muscle.
10/28/2014 1:00:00 AM
KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters.
9/17/2014 1:00:00 AM
KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, will give a presentation titled “Translatable Dynamic Biomarkers: The Future of Biomarkers in Neurodegenerative Diseases” at the 8th Annual Neurodegenerative Conditions Research & Development Conference. The presentation will take place on Friday, September 19th, from 12:55‐1:20 p.m. PDT at the Sheraton Fisherman's Wharf Hotel San Francisco, California as part of the session titled “Biomarkers: Translation from Discovery to Clinical.”
9/4/2014 1:00:00 AM
KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.
6/4/2014 1:00:00 AM
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
5/22/2014 1:00:00 AM
KineMed Inc. today announced the appointment of Patrick James Doyle as Executive Vice President & Chief Business Officer. Doyle joins KineMed from PPD where he most recently served as Vice President, Strategic Partnerships.
5/19/2014 1:00:00 AM
EMERYVILLE, CA, May 19, 2014, – KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions.
5/13/2014 1:00:00 AM
EMERYVILLE, CA, May 13, 2014 – KineMed Inc. today announced the hire of Bill Evans as Executive Vice President, Muscle and Health Division.
5/1/2014 1:00:00 AM
EMERYVILLE, CA, May 1st, 2014, – KineMed, Inc. announced today that Dr. Scott Turner, KineMed’s EVP of Research, and Dr. Carine Beyson, KineMed’s Director of Clinical Metabolic Research, will present new data from type 2 diabetes patients in two posters highlighting KineMed’s biomarker technology at the American Heart Association’s Annual Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Meeting.
4/21/2014 1:00:00 AM
KineMed, Inc. announced participation in a global, two year, multi-organization effort to advance and standardize a single mouse model of early diabetic disease detection and progression. The two year effort brings together cutting edge expertise and technology with a goal to produce a new mouse research model system that can streamline the research and development of advances in diabetic research and improve the clinical success of programs using the model.
4/4/2014 1:00:00 AM
KineMed, Inc. announced today that Dr. Marc Hellerstein, KineMed’s President and CSO, will give an invited presentation titled “Quantifying in vivo metabolic pathway fluxes and network dynamics using heavy water and mass spectrometry: A new class of disease biomarkers” at the American Association for Cancer Research Annual Meeting, taking place April 5-9, in San Diego, California.
3/20/2014 1:00:00 AM
KineMed, Inc. announced today that abstracts were accepted for three oral and four poster presentations highlighting its work in liver fibrosis at the Keystone Fibrosis Symposium taking place March 23–28, 2014 in Keystone, Colorado. Dr. Scott Turner, KineMed’s Executive Vice President of Research, Dr. Claire Emson, KineMed’s Director of Fibrosis Research, and Dr. Martin Decaris, postdoctoral researcher in Cellular and Molecular Kinetics at KineMed, will represent KineMed at the conference.
3/19/2014 1:00:00 AM
KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, will give the presentation titled “Tracking Brain Function and Dysfunction Using Translational Kinetic BioMarkers”. Dr. Fanara’s presentation is today, from 11:05-11:30 AM PDT, at the Hyatt Regency Mission Bay San Diego, California as part of the 3rd Neurological Biomarkers Conference.
3/5/2014 2:00:00 AM
KineMed, Inc. announced today Marc Hellerstein, M.D., Ph.D., President, CSO, and Scientific Founder of KineMed, will lead the workshop titled “Flux Analysis” and give a presentation titled “Flux through target pathways and molecular networks as biomarkers for medical diagnostics and drug development.” Dr. Hellerstein’s presentation will take place today March 5th from 8:00-9:30 AM EST, at the Sanford Burnham Metabolic Origins of Disease Symposium taking place in Orlando, Florida.
2/27/2014 2:00:00 AM
EMERYVILLE, CA, February 27, 2014, – KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, Inc., will give a presentation titled “Translational kinetic biomarkers to enable the development of HTT-lowering therapies” at the CHDI Foundation’s 9th Annual Huntington's Disease Therapeutics Conference, taking place February 27th in Palm Springs, California
1/13/2014 2:00:00 AM
KineMed, Inc. announced an agreement with EMD Serono to apply KineMed’s mass spectrometric Dynamic Proteomics and lipids platforms to the discovery of protein and lipid biomarkers for multiple sclerosis.
1/13/2014 2:00:00 AM
KineMed, Inc. (www.kinemed.com) announced today that Timothy L. Enns has been hired as Chief Investor and Media Relations Officer. Mr. Enns most recently served as SVP of Corporate Communications and Marketing for Astex Pharmaceuticals (NASDAQ: ASTX), (formerly SuperGen, Inc. (SUPG)), which was acquired by Otsuka Pharmaceuticals.
12/10/2013 2:00:00 AM
In his presentation, titled “Advances in Biomarkers for Muscle Biology: Muscle Mass (Non-Invasive), Turnover of Muscle Proteome and ‘Virtual Biopsy’ of Muscle Protein Synthesis,” Marc Hellerstein, M.D., Ph.D., KineMed’s President, CSO, and Scientific Founder will discuss important advances in biomarker technology crucial to the development of treatments for muscle wasting diseases. Such diseases include cancer-related cachexia, sarcopenia, and Duchenne’s muscular dystrophy.
11/6/2013 2:00:00 AM
KineMed, Inc. today announced that Dr. Mahalakshmi Shankaran, Director of Muscle and Neurobiology at KineMed, Inc., will present preclinical data demonstrating the use of KineMed’s biomarker platform technology to measure the effects of Plexxikon’s FMS kinase inhibitor, PLX5622, on neuroinflammation at the 43rd annual meeting of the Society for Neuroscience being held in San Diego, California, November 9-13, 2013.
10/15/2013 1:00:00 AM
KineMed, Inc. announces an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.
9/23/2013 1:00:00 AM
Dr. Scott Turner, Executive Vice President of Research and Development at KineMed, Inc., will give a presentation titled “Dynamics of Lipoproteins and Cholesterol” at the 22nd Annual South East Lipid Research Conference.
9/18/2013 1:00:00 AM
Contract awarded under the Small Business Innovative Research Program (“SBIR”) to discover and validate kinetic blood based biomarkers for the diagnosis and monitoring of myocardial fibrosis
9/4/2013 1:00:00 AM
KineMed presents advances in kinetic biomarkers to diagnose and treat neurological disorders at the CNS Diseases World Summit 2013
8/27/2013 1:00:00 AM
David Fineman, KineMed’s Chairman and CEO will present “Leveraging Personal Biology Information for Precision Medicine and Wellness” at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 10th, from 12:30 to 12:55 EST.
8/20/2013 1:00:00 AM
K. Peter Hirth, Ph.D. Joins KineMed Board of Directors
5/21/2013 1:00:00 AM
KineMed Inc. announces an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc).
3/27/2013 12:00:00 AM
KineMed renews diabetes collaboration with Pfizer Inc
3/13/2013 12:00:00 AM
KineMed presents Applications of Kinetic Biomarkers to Diagnose and Treat Neurological Disorders at the 2nd Neurological Biomarkers Conference
2/21/2013 12:00:00 AM
KineMed, Isis and CHDI collaborate to advance therapeutic development for Huntington’s disease and develop novel biomarkers for pre-clinical and clinical use in drug development and therapeutic monitoring
1/3/2013 12:00:00 AM
KineMed, Inc.’s CEO David Fineman will present the first systems biology platform linking biologic measurements and targeted therapeutics to guide medicines development and clinical decision-making, at Biotech Showcase 2013
11/1/2012 12:00:00 AM
2012 North American Enabling Technology Award for Pathway Based Drug Discovery
10/3/2012 12:00:00 AM
“Pairing Diagnostics with Therapeutics: Biomarker Solutions for Personalized Medicine” will be presented by KineMed's CEO Mr. David Fineman at the 2012 BIO Investor Forum
9/11/2012 2:00:00 AM
Dr. Fanara will show what can be done with the KineMed platform to advance drug discovery, with examples from CNS research, illustrating how isotopic labeling can be used to study diseases and translate from pre-clinical into human studies.
9/10/2012 2:00:00 AM
Featured in the current issue of the Journal of Clinical Investigation, KineMed, Inc. announces an innovative class of biomarkers that enable scientists to track molecular transport changes in the brain during neurodegenerative diseases, in humans and preclinical models.
7/11/2012 2:00:00 AM
Marc Hellerstein MD PhD, KineMed Co-Founder and Chief of the Scientific Advisory Board will present “Proteome Dynamics: Measuring the Kinetics of Complex Networks in Cardiometabolic Disease” at the Kern Lipid Conference, July 12-15th, at the Vail Cascade Resort in Vail, Colorado
6/27/2012 2:00:00 AM
KineMed, Inc. receives $1.2 Million reinvestment from The Michael J. Fox Foundation for the further development of kinetic biomarkers predictive of Parkinson’s disease changes ahead of symptoms
6/18/2012 2:00:00 AM
KineMed, Inc. enters multi-year agreement with GlaxoSmithKline to develop kinetic biomarkers
6/13/2012 2:00:00 AM
Collaboration will utilize KineMed’s extensive experience in cholesterol metabolic studies and will quantify physiologic and pathologic brain lipid synthesis in HD.
Equities.com speaks with David Fineman, CEO of KineMed, Inc. at the Rodman & Renshaw Conference 2015.
David Fineman - Chairman and Chief Executive Officer
Building the Next Generation Drug Company: Medicines Development Based on the Biology of Human Disease
Marc K. Hellerstein, M.D., Ph.D. - Co-Founder and Chairman of the Scientific and Clinical Advisory Boards
watch video >>
KineMed's Shepherd Model: Advancing Clinical Stage Drug Candidates through the "Valley of Death"
Marc K. Hellerstein, M.D., Ph.D. - Co-Founder and Chairman of the Scientific and Clinical Advisory Boards
watch video >>